Abbott looking beyond anti-TNF agents for psoriasis
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Abbott plans to initiate a Phase III study of its fully human monoclonal antibody ABT-874 for psoriasis later this year, pending FDA feedback, the firm announces May 4. Targeting interleukin-12 and interleukin-23, the biologic could potentially be a first-in-class treatment for psoriasis. A previous 12-week, double-blind, placebo-controlled Phase II study enrolled 180 patients with moderate to severe psoriasis. Results showed that ABT-874 was significantly more effective than placebo, with 90 percent of patients achieving 75 percent improvement in the degree and severity of skin lesions in four of the five active treatment groups. Abbott's tumor necrosis factor inhibitor Humira (adalimumab) is pending at FDA for moderate to severe chronic plaque psoriasis (1Pharmaceutical Approvals Monthly April 2007, In Brief)...
You may also be interested in...
Abbott seeks Humira psoriasis claim
Abbott submits an sBLA for its tumor necrosis factor inhibitor Humira (adalimumab) for treatment of moderate to severe chronic plaque psoriasis, the company announced April 2. The submission is based on the results of two double-blind, placebo-controlled trials of Humira - REVEAL and CHAMPION - evaluating the biologic based on the Psoriasis Area and Severity Score. The 52-week REVEAL study evaluated more than 1,200 patients with moderate to severe chronic plaque psoriasis, for which 71 percent achieved PASI 75 or better compared to 6.5 percent on placebo. The 16-week CHAMPION study evaluated 271 patients; 80 percent of patients treated with Humira achieved PASI 75 or better compared to 36 percent treated with methotrexate. Humira gained a Crohn's indication Feb. 27, making it the first self-administered biologic approved for Crohn's (1Pharmaceutical Approvals Monthly March 2007, In Brief). The biologic is also approved for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.